<?xml version='1.0' encoding='utf-8'?>
<document id="32125665"><sentence text="Results from Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Effect of Finerenone on the Pharmacokinetics of Comedications."><entity charOffset="92-102" id="DDI-PubMed.32125665.s1.e0" text="Finerenone" /></sentence><sentence text="In vivo studies were performed with the novel, selective, non-steroidal mineralocorticoid receptor antagonist finerenone to assess the relevance of inductive and/or inhibitory effects on cytochrome P450 (CYP) enzymes observed in vitro" /><sentence text="" /><sentence text="CYP isoenzyme-specific substrates were incubated in vitro with finerenone or its metabolites to investigate reversible and irreversible inhibitory as well as inductive potential"><entity charOffset="63-73" id="DDI-PubMed.32125665.s4.e0" text="finerenone" /></sentence><sentence text=" Three crossover studies in healthy male volunteers investigated the effects of finerenone (20 mg orally) on the pharmacokinetics of the index substrates midazolam (CYP3A4, n = 30), repaglinide (CYP2C8, n = 28) and warfarin (CYP2C9, n = 24)"><entity charOffset="80-90" id="DDI-PubMed.32125665.s5.e0" text="finerenone" /><entity charOffset="182-193" id="DDI-PubMed.32125665.s5.e1" text="repaglinide" /><pair ddi="false" e1="DDI-PubMed.32125665.s5.e0" e2="DDI-PubMed.32125665.s5.e0" /><pair ddi="false" e1="DDI-PubMed.32125665.s5.e0" e2="DDI-PubMed.32125665.s5.e1" /></sentence><sentence text="" /><sentence text="Finerenone caused direct inhibitory effects on CYP activities in vitro in the rank order CYP2C8, CYP1A1 &gt; CYP3A4 &gt; CYP2C9 and CYP2C19, but not on other major CYP isoforms"><entity charOffset="0-10" id="DDI-PubMed.32125665.s7.e0" text="Finerenone" /></sentence><sentence text=" Moreover, irreversible inhibition of CYP3A4 was observed" /><sentence text=" The major metabolites of finerenone demonstrated minor reversible inhibition of CYP1A1, CYP2C9 and CYP3A4 with no hint of time-dependent inhibition of any CYP isoform"><entity charOffset="26-36" id="DDI-PubMed.32125665.s9.e0" text="finerenone" /></sentence><sentence text=" Calculations from in vitro data according to regulatory guidelines suggested likely inhibition of CYP2C8 and CYP3A4 in vivo, whereas this was not the case for CYP1A1, CYP2C9 and CYP2C19" /><sentence text=" Furthermore, finerenone and three of its metabolites were inducers of CYP3A4 in vitro with predicted weak-to-moderate in vivo relevance"><entity charOffset="14-24" id="DDI-PubMed.32125665.s11.e0" text="finerenone" /></sentence><sentence text=" Studies in healthy volunteers, prompted by these results, demonstrated no effect of finerenone on CYP isoenzymes for which in vitro data had indicated potential inhibition or induction"><entity charOffset="85-95" id="DDI-PubMed.32125665.s12.e0" text="finerenone" /></sentence><sentence text="" /><sentence text="Administration of finerenone 20 mg once daily confers no risk of clinically relevant drug-drug interactions with substrates of cytochrome P450 enzymes"><entity charOffset="18-28" id="DDI-PubMed.32125665.s14.e0" text="finerenone" /></sentence><sentence text="" /></document>